Guselkumab Induction Improves Moderate-to-Severe UC at Week 12

The drug was statistically superior to the placebo across all key endpoints in phase 2b study, regardless of patient response or intolerance to conventional and advanced therapies.

Related Keywords

David Rubin ,American College Of Gastroenterology ,Janssen Research Development ,Johnson ,American College ,Chicago Medicine Inflammatory Bowel Disease ,Janssen Research ,Ulcerative Colitis ,Endoscopy ,Inflammatory Bowel Disease ,Nflammatory Bowel Disease Ibd ,Bd ,Neoadjuvant ,Rectal Bleeding ,Ectal Hemorrhage ,Emorrhage Rectal ,Remission ,Statistics ,Anti Tnf ,Anti Tumor Necrosis Factor ,